Please ensure Javascript is enabled for purposes of website accessibility

Vir Biotechnology and GlaxoSmithKline Expand Their Partnership

By Brian Orelli, PhD - Updated Feb 18, 2021 at 1:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech will get $345 million through an upfront payment and equity investment.

Vir Biotechnology (VIR -2.29%) and GlaxoSmithKline (GSK 2.20%) have gone from dating to a full-blown relationship in under a year. Could a marriage be next?

Last April, the duo hooked up to develop antibody treatments and preventive options for COVID-19. As part of the deal, GlaxoSmithKline took a $250 million stake in Vir.

The giant British drugmaker must have liked what it saw in the American biotech because it is expanding its relationship with Vir to include treatments for influenza. The deal gives GlaxoSmithKline an exclusive option to co-develop Vir's lead flu treatment, VIR-2482, and includes a three-year research collaboration on next-generation antibodies for the prevention or treatment of the flu, as well as antibody treatments for up to three undisclosed targets. The companies are also expanding their functional genomics collaboration beyond the coronavirus into other respiratory virus targets.

Doctor listening to a patient's chest with a stethoscope

Image source: Getty Images.

Vir will get a $225 million payment up front, and GlaxoSmithKline is also investing another $120 million in the biotech. If GlaxoSmithKline exercises its license to co-develop VIR-2482 at the end of phase 2 development, Vir will get another $300 million. Vir will also be eligible for up to $200 million in regulatory milestone payments.

It's easy to imagine that GlaxoSmithKline might just buy Vir outright at some point, considering it already owns a big chunk of the biotech and it's on the hook for some major payments. But complicating such a potential marriage are Vir's other relationships with Alnylam Pharmaceuticals (ALNY 2.25%) and Gilead Sciences (GILD 0.90%). GlaxoSmithKline may not be interested in an acquisition that comes with extra baggage.

Whether the relationship ends in a full union or not, Vir's shareholders are justifiably excited about GlaxoSmithKline's increased interest in the company. As of 2:10 pm EST, shares of Vir were up by 16.2%.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
VIR
$24.36 (-2.29%) $0.57
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$63.84 (0.90%) $0.57
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
GSK
$44.52 (2.20%) $0.96
Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
ALNY
$132.27 (2.25%) $2.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.